Key statistics
As of last trade Beigene Ltd (49BA:FRA) traded at 183.00, -5.67% below its 52-week high of 194.00, set on Sep 11, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 177.00 |
---|---|
High | 183.00 |
Low | 177.00 |
Bid | 181.00 |
Offer | 183.00 |
Previous close | 178.00 |
Average volume | 66.22 |
---|---|
Shares outstanding | 106.08m |
Free float | 102.83m |
P/E (TTM) | -- |
Market cap | 21.79bn USD |
EPS (TTM) | -5.08 USD |
Data delayed at least 15 minutes, as of Sep 20 2024 15:14 BST.
More ▼
Press releases
- BeiGene Receives Israeli Ministry of Health Approval for TEVIMBRA® for the Treatment of Oesophageal Squamous Cell Carcinoma (OSCC) After Prior Chemotherapy
- BeiGene Announces Updates to Commercial Leadership Team
- BeiGene Highlights TEVIMBRA® Data in Lung and Gastrointestinal Cancers at ESMO 2024
- BeiGene to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
- BeiGene’s BGB-16673 Receives U.S. FDA Fast Track Designation for CLL/SLL
- BeiGene Enters Next Phase of Global Growth with Announcement of Second Quarter 2024 Financial Results and Corporate Updates
- BeiGene Opens Flagship U.S. Biologics Manufacturing and Clinical R&D Facility, Continues Global Expansion to Deliver Medicines to More Patients Around the World
- BeiGene Announces Appointment of Aaron Rosenberg as Chief Financial Officer
More ▼